Ccrf cem

Human cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). CCRF‐CEM (T‐ALL), K‐562 (chronic myeloid leucemia), PC‐3 (prostate carcinoma), HT‐29 (colon carcinoma), HTB‐54 (lung carcinoma), MOLT‐4 (T‐ALL) and A549 (lung carcinoma) cells were grown in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% foetal bovine serum (FBS). MCF‐7 (breast adenocarcinoma) cells were grown in EMEM (ATCC) supplemented with 10% FBS. In addition, 184B5 (non‐malignant, mammary‐gland derived) cells were grown in Hams F12/DMEM (50:50) supplemented as previously described 12. BEAS‐2B (non‐malignant, derived from bronchial epithelium) were grown in RPMI 1640 supplemented with 5% FBS, 1× insulin‐transferrin‐sodium selenite (ITS), 500 ng/ml hydrocortisone, 2 mM sodium pyruvate, 2 mM glutamine, 20 mg/ml penicillin/gentamicin, 20 ng/ml epidermal growth factor (EGF) and 0.3 nM retinoic acid. Media were renewed every 2 days, and cells were subcultured at a ratio of 1:3.

HL60 (acute promyelocytic leukemia), MOLT-4 (acute lymphoblastic leukemia) and CCRF-CEM (acute lymphoblastic leukemia), BEAS (normal human bronchial epithelium) and HUVEC (Human umbilical vein endothelial cell) were purchased from BCRC (Bioresource Collection and Research Centre, Taiwan); NCI/ADR-RES (National Cancer Institute/Adriamycin-Resistant, human ovarian carcinoma cell line) was obtained from the DTP Human Tumor Cell Line Screen; MV4-11(acute myeloid leukemia cell) and MOLM-13 (acute myeloid leukemia cell) were kindly gifted from National Health Research Institutes. HL60, MOLT-4, CCRF-CEM, BEAS, MV4-11, MOLM-13 and NCI/ADR-RES were maintained in RPMI-1640 medium (Invitrogen) supplemented with 10% FBS. HUVEC were grown in endothelial cell medium (ECM) (ScienCell Research Laboratory, Carlsbad, CA) supplemented with 20% FBS. All cell lines were incubated in 5% CO₂ at 37°C. B392 was synthetized from Prof. Jing-Ping Liou (Taipei Medical University), and the purity is over 98%. Paclitaxel and vincristine were purchased from Sigma (St. Louis, MO). All of the above drugs were reconstituted in dimethysulfoxide (DMSO).

Cervical cancer (HeLa), acute monocytic leukemia (Thp1), colorectal carcinoma (Colo-205) and cecum carcinoma (LS-513) cells were maintained in Roswell Park Memorial Institute (RPMI) medium (Lonza, Cologne, Germany) supplemented with 100 mg/mL of streptomycin, 100 units/mL of penicillin and 10% of heat-inactivated fetal bovine serum. Other cell lines: human leukemia (CCRF-CEM); acute promyelocytic leukemia (NB-4); human lymphoma (U937); prostate cancer (DU-145 and PC3); hepatocellular carcinoma (HepG2); breast adenocarcinoma (MCF-7 and MDA-MB-231); Vero; and Hep-2 cells, were sub-cultured on Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen, California, USA), and incubation was conducted at 37 °C in a humidified atmosphere with 5% CO₂. The cell lines were obtained from Nawah Scientific Inc. (Mokatam, Cairo, Egypt), while primary peripheral blood mononuclear cells (PBMCs) and normal human (ATCC^® PCS-800-011™) cells were purchased from Vascera, Cairo, Egypt. This work was approved by the Ethical Research Committee of the Faculty of Pharmacy, Ain Shams University (Approval No. 294).

ALL cell lines, including Jurkat, CCRF-CEM, CEM/C1, Nalm6, Sup-B15, THP-1, HL-60, and Reh cells, and the human embryonic kidney cell line 293T, were purchased from the National Collection of Authenticated Cell Cultures (Shanghai, China). CCRF-CEM, CEM/C1, Nalm6, and Reh cells were cultured in RPMI 1640 medium (Gibco, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Corning, New Zealand Sourced), and 1% penicillin–streptomycin (Gibco). Jurkat cells were cultured with RPMI 1640 containing 10% FBS, 1% GlutaMAX (Gibco), and 1% penicillin–streptomycin. THP-1 cells were cultured in RPMI 1640 containing 10% FBS, 0.05 mmol/l β-Mercaptoethanol (Gibco), and 1% penicillin–streptomycin. HL-60 and Sup-B15 cells were cultured in IMDM (Gibco) containing 20% FBS and 1% penicillin–streptomycin. 293T cells were cultured with Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) containing 10% FBS and 1% penicillin–streptomycin. All cells were maintained at 37°C with 5% CO₂, and saturated humidity. Cells in the logarithmic growth phase were used for subsequent experiments. All cells were identified by short tandem repeat (STR) profiling and were mycoplasma negative.

PF-382, TALL-1, HPB-ALL, and Jurkat were purchased from DSMZ. CCRF-CEM and HEK293T cell lines were obtained from ATCC.
PF-382, TALL-1, CCRF-CEM, and Jurkat, were cultured in RPMI 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% fetal bovine serum (Lonza Group Ltd., Basel, Switzerland), 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, Thermo Fisher Scientific), and maintained at 37 °C in a 5% CO₂ atmosphere.
The HPB-ALL cell line was cultured in RPMI 1640 supplemented with 20% fetal bovine serum.
The HEK293T cell line was cultured in DMEM (Gibco, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin.

Human leukemia cells were obtained from residual samples on a protocol approved by the Institutional Review Board of Stony Brook University. Cord blood cells were also obtained under protocol from donors at Stony Brook University Hospital. Written, informed consent was obtained from all donors. KARPAS-299, HL-60, CCRF-CEM, MOLT4 and NK-92 cell lines were obtained from ATCC (Manassas, VA). NK-92 cells were cultured in filtered NK cell media, defined as alpha-MEM without ribonucleosides and deoxyribonucleosides with 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 12.5% heat-inactivated horse serum, 12.5% heat-inactivated FBS, 1X Pen/Strep, 0.2% inositol, 0.02% folic acid, and 50 uM beta-mercaptoethanol, supplemented with IL-2 (300 IU/mL), unless otherwise specified. KARPAS-299, CCRF-CEM, and MOLT4 cell lines were cultured in RPMI, 10% FBS, 1x Pen/Strep (Gibco, Waltham, MA, USA). HL-60 cells were cultured in IMDM, 10% FBS, 1x Pen/Strep (Gibco, Waltham, MA, USA).